FindTrial
Sign In

Markers of morbidity and death after gall bladder cancer surgery

Perioperative Inflammatory and nutritional makers of morbidity and mortality in gallbladder cancer: A Retrospective Study - NIL

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/12/098487
Enrollment
2000
Registered
2025-12-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C23- Malignant neoplasm of gallbladder

Interventions

Intervention1: Nil: Nil Intervention2: NA: NA Control Intervention1: NA: NA

Sponsors

Dr Sohan Lal Solanki
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients underwent gall bladder cancer surgery from January 2010 to Sept 2022.

Exclusion criteria

Exclusion criteria: 1. Inoperable cases 2. Patients with missing or incomplete hospital records.

Design outcomes

Primary

MeasureTime frame
Post-operative complications in terms of Clavien-Dindo Score.Timepoint: From Postoperative Day 0 to the Day of Discharge.—

Secondary

MeasureTime frame
30 Day Mortality, 90 Day Mortality, Disease Free Survival, Overall Survival and Fffect of Albumin Globulin Ratio (AGR), Neutrophil to Lymphocyte Ratio (NLR), Platelets to Lymphocyte Ratio (PLR). and Aspartate aminotransferase to Platelet Ratio Index APRI and effect of Delta-AGR, Delta-NLR, Delta-PLR and Delta-APRI on these variables. Timepoint: till 30 day, 90 day, 3 years overall survival and disease free survival—

Countries

India

Contacts

Public ContactDr Sohan Lal Solanki

Tata Memorial Hospital

sohan.solanki@gmail.com9869253201

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026